(Q40624109)

22 September 2017

title

Anastrozole versus progestins/tamoxifen (English)

1 reference

22 September 2017

1 reference

1 reference

Thuerlimann Beat

1

1 reference

22 September 2017

publication date

1 November 2002

1 reference

European Journal of Cancer

22 September 2017

published in

1 reference

22 September 2017

volume

38 Suppl 6

1 reference

22 September 2017

page(s)

S49-51

1 reference

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Hormonal treatment of breast cancer: new developments

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900284-8

7 January 2021

10.1016/S0959-8049(02)00284-8

Identifiers

DOI

1 reference

22 September 2017

1 reference